Table 2

Ongoing phase 3 trials of first-line treatment with immune checkpoint inhibitors

TrialAgentHistology (SQ or no-SQ)No. of patientsExperimental armPD-L1 status
CheckMate 227
(NCT02477826)
NivolumabBoth1980Arm A: nivolumab.
Arm B: nivolumab+ipilimumab.
Arm C: SOC+nivolumab.
All comers
KEYNOTE-042
(NCT02220894)
PembrolizumabBoth1240Arm A: pembrolizumab.
Arm B: chemotherapy.
Positive
>1%
KEYNOTE-407
(NCT02775435)
PembrolizumabSQ560Arm A: SOC.
Arm B: SOC+pembrolizumab.
All comers
KEYNOTE-189
(NCT02578680)
PembrolizumabNo-SQ580Arm A: SOC.
Arm B: SOC+pembrolizumab.
All comers
NEPTUNE
(NCT02542293)
DurvalumabBoth960Arm A: durvalumab+tremilimumab.
Arm B: SOC.
All comers
PEARL
(NCT03003962)
DurvalumabBoth440Arm A: durvalumab.
Arm B: SOC.
Positive≥25%
IMpower 110
(NCT02409342)
AtezolizumabBoth570Arm A: SOC.
Arm B: atezolizumab.
Positive
TC 2/3 or IC 2/3
IMpower 130
(NCT02367781)
AtezolizumabNo-SQ650Arm A: SOC.
Arm B: SOC+atezolizumab.
All comers
IMpower 131
(NCT02367794)
AtezolizumabSQ1025Arm A: SOC.
Arm B: SOC+atezolizumab.
All comers
IMpower 132
(NCT02657434)
AtezolizumabNo-SQ568Arm A: SOC.
Arm B: SOC+atezolizumab.
All comers
IMpower 150
(NCT02366143)
AtezolizumabNo-SQ1200Arm A: SOC+bevacizumab.
Arm B: SOC+B+atezolizumab.
All comers
JAVELIN LUNG 100
(NCT02576574)
AvelumabBoth1095Arm A: SOC.
Arm B: avelumab.
Positive
≥1%
  • SOC, standard of care; SQ, sqamous.